|
The invention relates to materials and methods for
diagnosis and treatment of chronic fatigue syndrome/myalgic
encephalitis.
A number of genes are identified which are
expressed at abnormal levels in patients affected by CFS/ME as
compared to normal healthy individuals.
These genes include those encoding defensinα1, haemoglobin γ,
CXCR4, tubulin beta 1, serine/threonine kinase 17B, HLA DRss4 and prostaglandin D2 synthase.
The genes identified provide objective disease
markers that may be used in diagnostic tests to support the diagnosis
of CFS/ME or for monitoring the effectiveness of therapy.
They also provide a rational basis for classifying
CFS/ME patients according to the biochemical lesion underlying their symptoms
and enable provision of appropriate targeted therapies. |
